8PWC

Crystal structure of MDM2 with Brigimadlin

Summary for 8PWC

• Entry DOI: 10.2210/pdb8pwc/pdb
• Descriptor: E3 ubiquitin-protein ligase Mdm2, Brigimadlin (3 entities in total)
• Functional Keywords: inhibitor, complex, ligase
• Biological source: Homo sapiens (human)
• Total number of polymer chains: 3
• Total formula weight: 39551.58

Authors

Bader, G.,Wolkerstorfer, B. (deposition date: 2023-07-20, release date: 2024-10-02, Last modification date: 2024-12-11)

Primary citation

Gollner, A.,Rudolph, D.,Weyer-Czernilofsky, U.,Baumgartinger, R.,Jung, P.,Weinstabl, H.,Ramharter, J.,Grempler, R.,Quant, J.,Rinnenthal, J.,Perez Pitarch, A.,Golubovic, B.,Gerlach, D.,Bader, G.,Wetzel, K.,Otto, S.,Mandl, C.,Boehmelt, G.,McConnell, D.B.,Kraut, N.,Sini, P.
Discovery and Characterization of Brigimadlin, a Novel and Highly Potent MDM2-p53 Antagonist Suitable for Intermittent Dose Schedules.
Mol.Cancer Ther., 23:1689-1702, 2024

PubMed Abstract: p53 is known as the guardian of the genome and is one of the most important tumor suppressors. It is inactivated in most tumors, either via tumor protein p53 (TP53) gene mutation or copy number amplification of key negative regulators, e.g., mouse double minute 2 (MDM2). Compounds that bind to the MDM2 protein and disrupt its interaction with p53 restore p53 tumor suppressor activity, thereby promoting cell cycle arrest and apoptosis. Previous clinical experience with MDM2-p53 protein-protein interaction antagonists (MDM2-p53 antagonists) has demonstrated that thrombocytopenia and neutropenia represent on-target dose-limiting toxicities that might restrict their therapeutic utility. Dosing less frequently, while maintaining efficacious exposure, represents an approach to mitigate toxicity and improve the therapeutic window of MDM2-p53 antagonists. However, to achieve this, a molecule possessing excellent potency and ideal pharmacokinetic properties is required. Here, we present the discovery and characterization of brigimadlin (BI 907828), a novel, investigational spiro-oxindole MDM2-p53 antagonist. Brigimadlin exhibited high bioavailability and exposure, as well as dose-linear pharmacokinetics in preclinical models. Brigimadlin treatment restored p53 activity and led to apoptosis induction in preclinical models of TP53 wild-type, MDM2-amplified cancer. Oral administration of brigimadlin in an intermittent dosing schedule induced potent tumor growth inhibition in several TP53 wild-type, MDM2-amplified xenograft models. Exploratory clinical pharmacokinetic studies (NCT03449381) showed high systemic exposure and a long plasma elimination half-life in patients with cancer who received oral brigimadlin. These findings support the continued clinical evaluation of brigimadlin in patients with MDM2-amplified cancers, such as dedifferentiated liposarcoma.

PubMed: 39259562
DOI: 10.1158/1535-7163.MCT-23-0783

Experimental method

X-RAY DIFFRACTION (1.461 Å)